 Head and Neck Neoplasms
"Head and Neck Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)
| Descriptor ID |
D006258
|
| MeSH Number(s) |
C04.588.443
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Head and Neck Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Head and Neck Neoplasms".
This graph shows the total number of publications written about "Head and Neck Neoplasms" by people in this website by year, and whether "Head and Neck Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1980 | 2 | 0 | 2 | | 1981 | 7 | 1 | 8 | | 1982 | 2 | 0 | 2 | | 1983 | 2 | 1 | 3 | | 1984 | 3 | 0 | 3 | | 1985 | 6 | 1 | 7 | | 1986 | 2 | 0 | 2 | | 1987 | 2 | 1 | 3 | | 1988 | 6 | 0 | 6 | | 1989 | 8 | 1 | 9 | | 1990 | 4 | 2 | 6 | | 1991 | 7 | 2 | 9 | | 1992 | 10 | 2 | 12 | | 1993 | 11 | 0 | 11 | | 1994 | 10 | 1 | 11 | | 1995 | 8 | 2 | 10 | | 1996 | 7 | 1 | 8 | | 1997 | 3 | 1 | 4 | | 1998 | 6 | 0 | 6 | | 1999 | 13 | 1 | 14 | | 2000 | 14 | 2 | 16 | | 2001 | 9 | 3 | 12 | | 2002 | 9 | 0 | 9 | | 2003 | 12 | 1 | 13 | | 2004 | 15 | 1 | 16 | | 2005 | 13 | 1 | 14 | | 2006 | 14 | 1 | 15 | | 2007 | 15 | 2 | 17 | | 2008 | 17 | 2 | 19 | | 2009 | 19 | 1 | 20 | | 2010 | 16 | 4 | 20 | | 2011 | 16 | 1 | 17 | | 2012 | 14 | 1 | 15 | | 2013 | 13 | 2 | 15 | | 2014 | 32 | 3 | 35 | | 2015 | 23 | 2 | 25 | | 2016 | 30 | 3 | 33 | | 2017 | 21 | 1 | 22 | | 2018 | 16 | 4 | 20 | | 2019 | 21 | 2 | 23 | | 2020 | 19 | 1 | 20 | | 2021 | 20 | 1 | 21 | | 2022 | 12 | 0 | 12 |
To return to the timeline, click here.
Below are the most recent publications written about "Head and Neck Neoplasms" by people in Profiles.
-
Rosenberg AJ, Agrawal N, Pearson AT, Gooi Z, Blair E, Portugal L, Cursio JF, Juloori A, Chin J, Rouse K, Villaflor VM, Seiwert TY, Izumchenko E, Lingen MW, Haraf DJ, Vokes EE. Phase I study of nab-paclitaxel-based induction followed by nab-paclitaxel-based concurrent chemotherapy and re-irradiation in previously treated head and neck squamous cell carcinoma. Br J Cancer. 2022 11; 127(8):1497-1506.
-
Patel TR, Lee S, Tajudeen BA, Stenson K, Bhayani M, Al-Khudari S. Association of HPV status with survival after surgical salvage of oropharyngeal cancers. Am J Otolaryngol. 2022 Jul-Aug; 43(4):103491.
-
Yeh R, Amer A, Johnson JM, Ginat DT. Pearls and Pitfalls of 18FDG-PET Head and Neck Imaging. Neuroimaging Clin N Am. 2022 May; 32(2):287-298.
-
Pierce C, Ginat DT. Postsurgical and Postradiation Findings in the Head and Neck Imaging. Neuroimaging Clin N Am. 2022 May; 32(2):299-313.
-
Iida M, McDaniel NK, Kostecki KL, Welke NB, Kranjac CA, Liu P, Longhurst C, Bruce JY, Hong S, Salgia R, Wheeler DL. AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer. BMC Cancer. 2022 Apr 23; 22(1):447.
-
Korpics MC, Turchan WT, Koshy M, Spiotto MT. Decreased overall survival in patients with locally advanced head and neck cancer receiving definitive radiotherapy and concurrent cetuximab: National Cancer Database analysis. Head Neck. 2022 07; 44(7):1528-1544.
-
Cohen EEW, Nabell L, Wong DJ, Day T, Daniels GA, Milhem M, Deva S, Jameson M, Guntinas-Lichius O, Almubarak M, Strother M, Whitman E, Chisamore M, Obiozor C, Bagulho T, Gomez-Romo J, Guiducci C, Janssen R, Gamelin E, Algazi AP. Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial. Clin Cancer Res. 2022 03 15; 28(6):1157-1166.
-
Gillison ML, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Jayaprakash V, Wei L, Ferris RL. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141. Oncologist. 2022 03 04; 27(2):e194-e198.
-
Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EEW, Coussens LM. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study. Clin Cancer Res. 2022 Mar 01; 28(5):903-914.
-
Bourhis J, Burtness B, Licitra LF, Nutting C, Schoenfeld JD, Omar M, Bouisset F, Nauwelaerts H, Urfer Y, Zanna C, Cohen EE. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design. Future Oncol. 2022 May; 18(14):1669-1678.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|